Interstitial cystitis/bladder pain syndrome
- IC/BPS pathophysiology:IC/BPS is characterised by bladder pain, urgency, frequency, and pelvic discomfort without identifiable infection. Urothelial barrier defects (reduced GAG layer — glycosaminoglycan) allow urinary solutes to penetrate the urothelium, triggering mast cell degranulation and neurogenic inflammation. NOX2-derived ROS in urothelial cells and bladder mast cells amplify this inflammatory cycle.
- Mast cell infiltration:Bladder biopsies in IC/BPS show increased mast cell density in the detrusor muscle and submucosa. Mast cells release histamine, tryptase, and leukotriene LTC4/LTD4. Spirulina’s GLA/DGLA pathway reduces LTC4/LTD4 production — the same mechanism as in systemic MCAS, applied locally to bladder mast cells.
- Neurogenic inflammation:Substance P and CGRP release from bladder afferent neurons sensitises the urothelium. Chronic neurogenic inflammation in IC/BPS overlaps with central sensitisation — patients often have comorbid fibromyalgia, IBS, and vulvodynia. The same NOX2 neuroinflammatory pathway is relevant across these overlapping conditions.
Recurrent UTI and microbiome
- Recurrent UTIs (3+ per year in women) involve E. coli reservoirs in intestinal and periurethral flora. The gut microbiome composition determines the pool of potential uropathogens. Spirulina polysaccharides stimulate Lactobacillus species and Bifidobacterium — bacteria associated with reduced intestinal E. coli overgrowth and reduced recurrent UTI frequency in observational studies.
- D-mannose and cranberry PACs (proanthocyanidins) prevent E. coli adhesion to urothelium via anti-adhesin mechanisms. Spirulina does not provide significant D-mannose or PACs — the gut microbiome modulation is the primary recurrent UTI mechanism of interest.
- Spirulina taken alongside cranberry extract (providing 36 mg PAC/day) addresses both sides of recurrent UTI prevention: microbiome optimisation (spirulina) and urothelial adhesion blockade (cranberry).
Bladder cancer context
- Phycocyanin has shown anti-proliferative and pro-apoptotic effects in bladder cancer cell lines in vitro (T24, RT4, 5637 cells) via ROS modulation and NF-κB inhibition. No clinical evidence in bladder cancer patients exists.
- BCG intravesical therapy (for non-muscle-invasive bladder cancer, NMIBC) works via immune activation — spirulina’s NK stimulation is directionally complementary to BCG-induced immune activation in the bladder in this specific context. This is speculative; discuss with the urological oncologist.
- Spirulina during cytotoxic chemotherapy for muscle-invasive bladder cancer (gemcitabine/cisplatin): see the cancer chemotherapy interactions article for cisplatin nephrotoxicity context. The potassium content of spirulina is relevant if on cisplatin (which causes hypomagnesaemia and hypokalaemia).
Practical guidance for IC/BPS
- Start at 1–2 g/day — IC/BPS patients often have multiple chemical sensitivities and mast cell reactivity similar to MCAS; the same slow titration approach applies
- Avoid high doses if symptoms worsen — some IC/BPS patients react to spirulina proteins as bladder irritants. Monitor urinary symptoms at each dose increase.
- The GLA/DGLA leukotriene reduction and NOX2 inhibition mechanisms are most relevant to IC/BPS; the gut microbiome modulation is most relevant to recurrent UTI
- 3–5 g/day if well tolerated; cold liquid format (shots, cold water) reduces GI exposure and avoids any potential bladder mucosa irritation from concentrated supplements
- Discuss with urologist or gynaecologist before starting in IC/BPS — particularly if on intravesical therapies (DMSO, heparin, lidocaine)